Cantor Louis B
Department of Ophthalmology, Indiana University Medical Center, Indianapolis, IN 46202, USA.
Expert Opin Pharmacother. 2002 Dec;3(12):1753-62. doi: 10.1517/14656566.3.12.1753.
Bimatoprost, a prostamide, effectively lowers intraocular pressure (IOP) in patients with open-angle glaucoma and ocular hypertension. In clinical trials, bimatoprost has demonstrated superiority to the beta-adrenergic antagonist timolol and has consistently provided approximately 1-2 mmHg greater mean IOP lowering than the prostaglandin latanoprost. Bimatoprost is more effective than either timolol or latanoprost in allowing patients to reach the low target pressures that best protect the visual field. Patients on bimatoprost therapy achieve low pressures throughout the day and night. Moreover, 1-year trials have shown that the efficacy of bimatoprost is sustained with long-term use. The most common side effects have been conjunctival hyperaemia, graded as trace or mild, and eyelash growth. No safety concerns have arisen in postmarketing surveillance. Bimatoprost appears to be a valuable new agent for glaucoma therapy.
比马前列素是一种前列腺酰胺，可有效降低开角型青光眼和高眼压症患者的眼压（IOP）。在临床试验中，比马前列素已证明优于β-肾上腺素能拮抗剂噻吗洛尔，并且始终比前列腺素拉坦前列素平均多降低约1-2 mmHg的眼压。在使患者达到最能保护视野的低目标眼压方面，比马前列素比噻吗洛尔或拉坦前列素更有效。接受比马前列素治疗的患者在白天和夜间均可达到低眼压。此外，为期1年的试验表明，长期使用比马前列素疗效持续。最常见的副作用是结膜充血，分级为微量或轻度，以及睫毛生长。上市后监测未出现安全问题。比马前列素似乎是一种有价值的青光眼治疗新药。
